AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1863126 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 6848894 — intervention group
Group type: EXPERIMENTAL
Intervention: Running program (average at least 8 miles per week)
Number of subjects: 81
Study 6848894 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 81
Study 31401679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod intake (750 g/week for 8 weeks)
Number of subjects: 62
Study 31401679 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon intake (750 g/week for 8 weeks)
Number of subjects: 62
Study 31401679 — intervention group
Group type: COMPARATOR
Intervention: Control group (fish-free diet for 8 weeks)
Number of subjects: 62
Study 30935953 — intervention group
Group type: EXPERIMENTAL
Intervention: R-pina (375 mg/m2 rituximab plus 2.4 mg/kg pinatuzumab vedotin)
Number of subjects: 123
Study 30935953 — intervention group
Group type: EXPERIMENTAL
Intervention: R-pola (375 mg/m2 rituximab plus 2.4 mg/kg polatuzumab vedotin)
Number of subjects: 123
Study 30935953 — intervention group
Group type: EXPERIMENTAL
Intervention: R-pina
Number of subjects: 123
Study 30935953 — intervention group
Group type: EXPERIMENTAL
Intervention: R-pola
Number of subjects: 123
Study 28556917 — intervention group
Group type: EXPERIMENTAL
Intervention: AML02 protocol
Number of subjects: 0
Study 28556917 — intervention group
Group type: EXPERIMENTAL
Intervention: AML02 protocol (low-risk AML)
Number of subjects: 0
Study 28556917 — intervention group
Group type: COMPARATOR
Intervention: AML97 protocol
Number of subjects: 0
Study 28077162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed inhaled nitrous oxide/oxygen mixture
Number of subjects: 240
Study 28077162 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard pain treatment (oral immediate-release morphine) plus nitrous oxide/oxygen mixture
Number of subjects: 240
Study 28077162 — intervention group
Group type: COMPARATOR
Intervention: Standard pain treatment (oral immediate-release morphine) plus oxygen
Number of subjects: 240
Study 23718718 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch (15 mg/16 hour)
Number of subjects: 117
Study 23718718 — intervention group
Group type: COMPARATOR
Intervention: Varenicline plus placebo patch
Number of subjects: 117
Study 23718718 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus nicotine patch
Number of subjects: 117
Study 21360754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 100
Study 21360754 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate treatment
Number of subjects: 100
Study 21360754 — intervention group
Group type: COMPARATOR
Intervention: Overall sample (Lithium and Valproate)
Number of subjects: 100
Study 18955565 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT) followed by autologous purged stem cell transplantation (ASCT)
Number of subjects: 172
Study 18955565 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 172
Study 17158144 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant warmer
Number of subjects: 62
Study 17158144 — intervention group
Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 62
Study 15043562 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosoft software for RBC ordering based on Hb content
Number of subjects: 51
Study 15043562 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemosoft software
Number of subjects: 51
Study 11915269 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair biking therapy for 2 weeks
Number of subjects: 40
Study 11915269 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 10443306 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic method (Group B)
Number of subjects: 120
Study 10443306 — intervention group
Group type: COMPARATOR
Intervention: Classical method (Group A)
Number of subjects: 120
Study 7982137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 20
Study 7982137 — intervention group
Group type: COMPARATOR
Intervention: Control group (Vecuronium 0.1 mg/kg without diazepam)
Number of subjects: 20
Study 2735178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sighing during mechanical ventilation
Number of subjects: 14
Study 2735178 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthetic without sighing
Number of subjects: 14
Study 807170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dudrick's method (20% glucose and a nitrogen source)
Number of subjects: 6
Study 807170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid method (12% glucose, a nitrogen source and soybean fat emulsion)
Number of subjects: 6
Study 807170 — intervention group
Group type: COMPARATOR
Intervention: Babson's method (12% glucose, a nitrogen source and 1% alcohol)
Number of subjects: 6
Study 807170 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral fat free nutrition (primary caloric source glucose)
Number of subjects: 6
Study 30228338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential seeding
Number of subjects: 0
Study 30228338 — intervention group
Group type: COMPARATOR
Intervention: Single stage seeding
Number of subjects: 0
Study 30228338 — intervention group
Group type: COMPARATOR
Intervention: Greedy approach
Number of subjects: 0
Study 28258601 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 361
Study 28258601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 361
Study 28258601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) and Prednisolone (Pred)
Number of subjects: 361
Study 26314577 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised multidimensional physical activity feedback and self-monitoring alongside trainer-supportive sessions
Number of subjects: 216
Study 26314577 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioner (GP) and standardised messages about physical activity for health
Number of subjects: 216
Study 26314577 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised feedback regarding the multidimensional nature of physical activity
Number of subjects: 216
Study 23201472 — intervention group
Group type: EXPERIMENTAL
Intervention: GM+G-CSF
Number of subjects: 50
Study 23201472 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 50
Study 18421508 — intervention group
Group type: COMPARATOR
Intervention: Model A (traditional counseling/testing)
Number of subjects: 251
Study 18421508 — intervention group
Group type: EXPERIMENTAL
Intervention: Model B (nurse‐initiated screening, traditional counseling/testing)
Number of subjects: 251
Study 18421508 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C (nurse‐initiated screening, streamlined counseling/rapid testing)
Number of subjects: 251
Study 16555172 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment (NPT)
Number of subjects: 91
Study 16555172 — intervention group
Group type: COMPARATOR
Intervention: Readmission status
Number of subjects: 91
Study 12669307 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated magnetic field exposure (magnetic flux density >or= 0.2 microT, or residential distance from major power lines <or= 100 m)
Number of subjects: 577
Study 12669307 — intervention group
Group type: COMPARATOR
Intervention: Background magnetic field exposure (magnetic flux density < 0.2 microT or > 100 m from major power lines)
Number of subjects: 577
Study 10746118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component interventions targeting major risk factors for falls (education, exercise, home safety advice, medical assessment)
Number of subjects: 252
Study 10746118 — intervention group
Group type: COMPARATOR
Intervention: Control group (information session only)
Number of subjects: 252
Study 9172113 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy system (intraabdominal fan retractor and electrically powered mechanical arm)
Number of subjects: 18
Study 9172113 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 pneumoperitoneum laparoscopy
Number of subjects: 18
Study 7527608 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (125 micrograms/hour)
Number of subjects: 33
Study 7527608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30181203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored phone intervention
Number of subjects: 1196
Study 30181203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Web + phone intervention
Number of subjects: 1196
Study 30181203 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1196
Study 26272687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical laminaria dilator
Number of subjects: 150
Study 26272687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (200 μg)
Number of subjects: 150
Study 26272687 — intervention group
Group type: COMPARATOR
Intervention: Mechanical dilation
Number of subjects: 150
Study 26272687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 150
Study 25170230 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Number of subjects: 720
Study 25170230 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 7 days
Number of subjects: 720
Study 25170230 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Number of subjects: 720
Study 25170230 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg) for 10 days
Number of subjects: 720
Study 23176379 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (time-released garlic-based drug)
Number of subjects: 196
Study 23176379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 20581879 — intervention group
Group type: EXPERIMENTAL
Intervention: Late mRNA-based (NucliSens CMV pp67) anti-HCMV treatment
Number of subjects: 130
Study 20581879 — intervention group
Group type: COMPARATOR
Intervention: PCR-based preemptive HCMV-directed antiviral therapy
Number of subjects: 130
Study 20581879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both late mRNA-based and PCR-based therapies
Number of subjects: 130
Study 18463998 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments (four types) for cocaine dependence
Number of subjects: 487
Study 18463998 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol services (additional treatment services)
Number of subjects: 487
Study 16527699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution colonoscopy with chromoscopy (HRC)
Number of subjects: 203
Study 16527699 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 203
Study 12954249 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bridging external fixator
Number of subjects: 0
Study 12954249 — intervention group
Group type: COMPARATOR
Intervention: Bridging external fixator
Number of subjects: 0
Study 10731499 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium alone (load A)
Number of subjects: 11
Study 10731499 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium with 35 g lactose (load B)
Number of subjects: 11
Study 10731499 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium with 17.5 g glucose and 17.5 g galactose (load C)
Number of subjects: 11
Study 8941092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin infusion (250 IU primed, 600 IU/h continuous)
Number of subjects: 11
Study 8941092 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study 8941092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/insulin period
Number of subjects: 11
Study 1490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 0.5 mg
Number of subjects: 31
Study 1490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 1.0 mg
Number of subjects: 31
Study 1490690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg
Number of subjects: 31
Study 1490690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3917652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 193
Study 3917652 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + ftorafur (FT‐E)
Number of subjects: 193
Study 3917652 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + FT‐E + Adriamycin
Number of subjects: 193
Study 31333058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic propulsion (350 kHz frequency, ≤200 W/cm2 focal intensity, ≤3‐second bursts per push)
Number of subjects: 18
Study 29577536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 60
Study 29577536 — intervention group
Group type: COMPARATOR
Intervention: Insulin pump therapy (control)
Number of subjects: 60
Study 27309523 — intervention group
Group type: EXPERIMENTAL
Intervention: A-polyaminopropyl biguanide + polyquaternium
Number of subjects: 236
Study 27309523 — intervention group
Group type: EXPERIMENTAL
Intervention: POLYQUAD + Aldox
Number of subjects: 236
Study 27309523 — intervention group
Group type: EXPERIMENTAL
Intervention: alexidine + polyquaternium‐1
Number of subjects: 236
Study 27309523 — intervention group
Group type: COMPARATOR
Intervention: hydrogen peroxide
Number of subjects: 236
Study 26842195 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J pouch (CJP) neorectum
Number of subjects: 42
Study 26842195 — intervention group
Group type: COMPARATOR
Intervention: Straight anastomosis (SA)
Number of subjects: 42
Study 23924302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including universal nutritional screening, oral nutritional supplements, red trays, and additional feeding support
Number of subjects: 120
Study 23924302 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 120
Study 20388217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fasting for 12 hours prior to the fasting trial
Number of subjects: 22
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision+Action
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Action
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Size
Number of subjects: 0
Study 18082300 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape
Number of subjects: 0
Study 16137945 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 1,200-1,500 mg/day (WHO, North America, Europe)
Number of subjects: 0
Study 16137945 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake of 800 mg/day (Japan)
Number of subjects: 0
Study 16137945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake of 10-20 microg/day (most countries)
Number of subjects: 0
Study 16137945 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D intake of 5 microg/day (Japan)
Number of subjects: 0
Study 16137945 — intervention group
Group type: EXPERIMENTAL
Intervention: General dietary guidelines (optimal body weight, adequate protein intake, balanced diet, avoiding excess sodium and caffeine)
Number of subjects: 0
Study 16137945 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K and other vitamins and minerals intake guidelines (not included in most countries)
Number of subjects: 0
Study 12900301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg)
Number of subjects: 63
Study 12900301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg) with enhanced community-based skills training
Number of subjects: 63
Study 12900301 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (low dose)
Number of subjects: 63
Study 10469192 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole, 20 mg twice daily, plus amoxicillin, 1 gm twice daily, and clarithromycin, 500 mg twice daily for 10 days
Number of subjects: 243
Study 10469192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, 40 mg daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Number of subjects: 243
Study 10469192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, 40 mg twice daily, plus amoxicillin and clarithromycin at the same doses as those of group Ome40
Number of subjects: 243
Study 7549447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.3%)
Number of subjects: 41
Study 7549447 — intervention group
Group type: COMPARATOR
Intervention: Rifamycin (1%)
Number of subjects: 41
Study 2332744 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment scheduling and reminder postcards
Number of subjects: 0
Study 2332744 — intervention group
Group type: COMPARATOR
Intervention: Control group (examined, informed about mammography, instructed to make an appointment)
Number of subjects: 0
Study 74660 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt restriction
Number of subjects: 31
Study 74660 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Number of subjects: 31
Study 74660 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 31
Study 30860603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alcohol to a target breath alcohol concentration (BrAC) of 0.06 g/dl
Number of subjects: 0
Study 29125558 — intervention group
Group type: EXPERIMENTAL
Intervention: B’more Healthy Communities for Kids (BHCK) intervention
Number of subjects: 365
Study 24785367 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation for 8 hours post-training
Number of subjects: 28
Study 24785367 — intervention group
Group type: COMPARATOR
Intervention: Control (normal attire) for 8 hours post-training
Number of subjects: 28
Study 24785367 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 28
Study 24785367 — intervention group
Group type: COMPARATOR
Intervention: Control (normal attire)
Number of subjects: 28
Study 24785367 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation and Control
Number of subjects: 28
Study 23363580 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sucrose diet
Number of subjects: 13
Study 23363580 — intervention group
Group type: COMPARATOR
Intervention: 15% sucrose diet
Number of subjects: 13
Study 22155721 — intervention group
Group type: EXPERIMENTAL
Intervention: Online completion of the Fatigue Symptom Inventory
Number of subjects: 1969
Study 22155721 — intervention group
Group type: COMPARATOR
Intervention: Offline completion of the Fatigue Symptom Inventory
Number of subjects: 1969
Study 22155721 — intervention group
Group type: EXPERIMENTAL
Intervention: Online completion of the SF-12v2
Number of subjects: 1969
Study 22155721 — intervention group
Group type: COMPARATOR
Intervention: Offline completion of the SF-12v2
Number of subjects: 1969
Study 22155721 — intervention group
Group type: EXPERIMENTAL
Intervention: Online completion of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 1969
Study 22155721 — intervention group
Group type: COMPARATOR
Intervention: Offline completion of the Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 1969
Study 22155721 — intervention group
Group type: EXPERIMENTAL
Intervention: Online completion of the single-item fatigue measure
Number of subjects: 1969
Study 22155721 — intervention group
Group type: COMPARATOR
Intervention: Offline completion of the single-item fatigue measure
Number of subjects: 1969
Study 19200175 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 200 mg bid
Number of subjects: 191
Study 19200175 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 400 mg bid
Number of subjects: 191
Study 19200175 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 800 mg qd
Number of subjects: 191
Study 19200175 — intervention group
Group type: COMPARATOR
Intervention: 3TC/ZDV
Number of subjects: 191
Study 16673683 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 176
Study 16673683 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 176
Study 15288626 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group) - standard Vicryl ligation
Number of subjects: 379
Study 15288626 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - Vicryl ligation followed by Prolene oversewing
Number of subjects: 379
Study 15288626 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C - Ethibond ligation
Number of subjects: 379
Study 15288626 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D - Ethibond ligation followed by Prolene oversewing
Number of subjects: 379
Study 15288626 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial closure (Groups B and D combined)
Number of subjects: 379
Study 11319192 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumarins with target INR of 2.1 to 4.8 during angioplasty and 6-month follow-up
Number of subjects: 530
Study 11319192 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal anticoagulation (INR in target range for at least 70% of follow-up time)
Number of subjects: 530
Study 9037327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50, 100, and 150 mg
Number of subjects: 71
Study 9037327 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 30, 60, and 90 mg
Number of subjects: 71
Study 9037327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg alone or combined with lisinopril 20 mg
Number of subjects: 71
Study 9037327 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 71
Study 8294833 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm tourniquet
Number of subjects: 40
Study 8294833 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm tourniquet
Number of subjects: 40